Prognosis
U.S. Names Drugmakers ‘Gaming’ Safety System to Shield Profits
- Gottlieb says transparency will elminate unnecessary hurdle
- Move is part of Trump administration plan to lower drug prices
This article is for subscribers only.
The Trump administration released a list of pharmaceutical companies including Gilead Sciences Inc. and Celgene Corp. that rivals say are blocking attempts to create cheaper generic versions of their products.
The move by the Food and Drug Administration is a major step by Commissioner Scott Gottlieb to end what he has called “gaming” of the system by branded drugmakers. The list, posted on the FDA website on Thursday, will be updated as generic manufacturers make the agency aware of further problems obtaining samples, he said.